JnJ to discontinue Phase 3 VENTURA development program evaluating aticaprant for major depressive disorder

Titusville: Johnson & Johnson has announced the decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depressive disorder (aMDD) due to insufficient efficacy in the target patient population.

The data confirmed aticaprant is safe and well-tolerated, and no new safety signals were identified. Based on the potential for this mechanism, the Company will explore future development opportunities for aticaprant in other areas of high unmet need.

According to WHO, Depressive disorder (also known as depression) is a common mental disorder. It involves a depressed mood or loss of pleasure or interest in activities for long periods of time. Depression is different from regular mood changes and feelings about everyday life. It can affect all aspects of life, including relationships with family, friends and community. Depression can happen to anyone. People who have lived through abuse, severe losses or other stressful events are more likely to develop depression. Women are more likely to have depression than men.